188 studies found for:    "Eye Diseases, Hereditary" OR "Peters plus syndrome"
Show Display Options
Rank Status Study
1 Active, not recruiting Efficacy and Safety of Oral Valproic Acid for Retinitis Pigmentosa
Conditions: Retinitis Pigmentosa;   Retinal Diseases;   Eye Diseases;   Eye Disease, Hereditary;   Retinal Degeneration
Intervention: Drug: Valproic Acid
2 Completed Fundus Changes in the Microphthalmy Eyes
Condition: Eye Diseases, Hereditary
Intervention:
3 Completed Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy
Conditions: Graves Ophthalmopathy;   Graves Disease;   Eye Diseases;   Thyroid Diseases;   Endocrine System Diseases;   Eye Diseases, Hereditary;   Hyperthyroidism;   Autoimmune Diseases;   Immune System Diseases
Intervention: Drug: Doxycycline
4 Recruiting Doxycycline Treatment in Mild Graves' Orbitopathy
Conditions: Graves Ophthalmopathy;   Graves Disease;   Eye Diseases;   Thyroid Diseases;   Endocrine System Diseases;   Eye Diseases, Hereditary;   Hyperthyroidism;   Autoimmune Diseases;   Immune System Diseases
Interventions: Drug: Doxycycline;   Drug: placebo
5 Completed Screening for Studies on Inherited Eye Diseases
Condition: Hereditary Eye Disease
Intervention:
6 Completed Evaluation and Treatment of Patients With Inherited Eye Diseases
Condition: Hereditary Eye Disease
Intervention:
7 Withdrawn Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD
Conditions: Choroidal Neovascularization;   Myopia;   Punctate Inner Choroidopathy (PIC);   Multifocal Choroiditis;   Ocular Histoplasmosis Syndrome;   Central Serous Chorioretinopathy (CSC);   Angioid Streaks;   Trauma, or Hereditary Eye Diseases
Interventions: Drug: Bevacizumab (Avastin; Genentech, Inc.);   Drug: Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy
8 Recruiting Safety and Efficacy of Subretinal Implants for Partial Restoration of Vision in Blind Patients
Conditions: Retinitis Pigmentosa;   Retinal Degeneration
Intervention: Device: Device name: "Retina Implant model Alpha". Surgical implantation of medical device into eye
9 Recruiting Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Conditions: Muscular Dystrophy;   Congenital Muscular Dystrophy;   Fukutin-related Protein Gene;   Limb Girdle;   FKRP Gene;   Childhood Onset LGMD;   Adult Onset LGMD;   POMT1;   POMT2;   POMGnT1;   LARGE;   Alpha Dystroglycan;   Dystroglycanopathy;   Centronuclear;   Multiminicore;   Multicore;   Minicore;   Congenital Fiber Type Disproportion;   Myotubular;   Nemaline;   Congenital Myopathy;   Neuromuscular;   Rigid Spine;   Phenotype-Genotype Correlation;   Cough Assisted Device;   Neuromuscular Disease;   Respiratory Exacerbation;   Invasive Ventilation;   Chest Physiotherapy;   Congenital Myopathies;   Genetic Mutations;   Hypertrophic Cardiomyopathy;   Wheelchair Use;   Cataract;   Opthalmoplegia;   Ullrich Congenital Muscular Dystrophy;   Intermediate Collagen VI Myopathy;   Laminin Alpha 2 Related Congenital Muscular Dystrophy;   MDC1A;   Merosin Deficient Congenital Muscular Dystrophy;   Congenital Muscular Dystrophy Undiagnosed;   Congenital Muscular Dystrophy Merosin Positive;   Walker Warburg Syndrome;   Muscle Eye Brain Disease;   Fukuyama;   Integrin Alpha 7 Deficiency;   Integrin Alpha 9 Deficiency;   Laminopathy;   Lamin AC;   SEPN 1 Related Myopathies;   Bethlem Myopathy;   Dystroglycanopathies;   LGMD2K;   LGMD2I;   LGMD2L;   LGMD2N;   Actin Aggregation Myopathy;   Cap Disease;   Central Core Disease;   Centronuclear Myopathy;   Core Rod Myopathy;   Hyaline Body Myopathy;   Multiminicore Myopathy;   Myotubular Myopathy;   Nemaline Myopathy;   Tubular Aggregate Myopathy;   Zebra Body Disease Myopathy;   Congenital Myopathy Other;   Reducing Body Myopathy;   Sarcotubular Myopathy;   Spheroid Body Myopathy
Intervention:
10 Completed Treatment of Congenital Stationary Night Blindness With an Alga Containing High Dose of Beta Carotene
Condition: Night Blindness
Intervention: Dietary Supplement: alga Dunaliella bardawil
11 Not yet recruiting Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues
Condition: Thyroid Associated Ophthalmopathies
Intervention: Drug: bimatoprost 0.03%
12 Not yet recruiting Observational Study of the Argus® II Retinal Prosthesis System
Condition: Retinitis Pigmentosa
Intervention:
13 Completed Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
Condition: Retinitis Pigmentosa
Intervention: Biological: intravitreal injection of autologous bone marrow stem cells
14 Withdrawn Study With Idebenone in Patients With Chronic Vision Loss Due to Leber's Hereditary Optic Neuropathy (LHON)
Condition: Leber's Hereditary Optic Neuropathy
Interventions: Drug: Idebenone;   Drug: Placebo
15 Completed Autologous Bone Marrow-Derived Stem Cells Transplantation For Retinitis Pigmentosa
Condition: Retinitis Pigmentosa
Intervention: Biological: intravitreal injection of autologous bone marrow stem cells
16 Not yet recruiting An Open Label Clinical Trial of Retinal Gene Therapy for Choroideremia
Condition: Choroideremia
Intervention: Genetic: rAAV2.REP1 vector
17 Completed Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy
Conditions: Coats' Disease;   Idiopathic Retinal Telangiectasia;   Retinal Angiomatous Proliferation;   Polypoidal Choroidal Vasculopathy;   Pseudoxanthoma Elasticum;   Pathological Myopia;   Multi-focal Choroiditis;   Rubeosis Iridis;   Von Hippel Lindau Disease;   BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Intervention: Drug: ranibizumab injection (0.5 mg)
18 Active, not recruiting Safety Study in Subjects With Leber Congenital Amaurosis
Condition: Leber Congenital Amaurosis
Intervention: Biological: AAV2-hRPE65v2
19 Unknown  Autoimmunity in Retinitis Pigmentosa
Condition: Retinitis Pigmentosa
Intervention: Drug: twice-daily dosage with 0.5% cyclosporine-A eyedrops
20 Active, not recruiting A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP)
Condition: Retinitis Pigmentosa
Interventions: Drug: rhNGF 60 µg/ml eye drops solution;   Drug: rhNGF 180 µg/ml eye drops solution;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years